This webinar will cover valuable insights, practical strategies, and expert advice on tackling the top benefits challenges in our current business climate.
We've created this guide to help you understand if your current employee savings program is in need of a reboot. We'll dive into nine questions that will help you better understand the state of your program and talk through what you can do to improve things you're falling short on.
We are living in an epidemic of chronic pain, with new cases occurring more often among adult Americans than with diabetes, depression or high blood pressure.
In 2024, for the first time, the number of new cancer diagnoses in the U.S. is projected to exceed 2 million. This sobering statistic was revealed alongside other cancer trends in the American Cancer Society's new Cancer Facts & Figures 2024 report.
Menopause is hot right now—and more and more companies are adding menopause care to their employee benefits packages. But a successful menopause program depends on a few key factors.
Learn about Stop Loss industry claim trends, including the impact of gene and cell therapies, and how they are affecting claim costs for self-funded employers.
Biologics are one of the fastest growing category of drugs—and one of the most expensive—making it challenging to balance cost with safety and efficacy. And it's even more challenging to incorporate unbranded biologics and biosimilars into benefits plans.
The American Cancer Society announced changes to its lung cancer screening guidelines, expanding their recommendations to all people over 50 who smoked more than 20 packs per year, and removing the minimum requirement for 'years since quitting.'
In the US, total healthcare spending related to cancer is projected to reach $246 billion by 2030– a 34% increase since 2015. With nearly 50% of the population receiving healthcare insurance through their employer, the lion's share of the cost increase has fallen on employers' shoulders.
